Results 41 to 50 of about 279,018 (287)

PSMB7 Is a Key Gene Involved in the Development of Multiple Myeloma and Resistance to Bortezomib

open access: yesFrontiers in Oncology, 2021
Multiple myeloma (MM), the second most commonly diagnosed hematologic neoplasm, is the most significant clinical manifestation in a series of plasma cell (PC) dyscrasia.
Dong Wu   +8 more
doaj   +1 more source

Common features between neoplastic and preneoplastic lesions of the biliary tract and the pancreas [PDF]

open access: yes, 2019
The bile duct system and pancreas show many similarities due to their anatomical proximity and common embryological origin. Consequently, preneoplastic and neoplastic lesions of the bile duct and pancreas share analogies in terms of molecular ...
Alvaro, D   +10 more
core   +1 more source

Recent advances in targeted therapy of colorectal cancer: impacts of monoclonal antibodies nanoconjugates [PDF]

open access: yesBioImpacts, 2019
Despite rapid advances in diagnostic and treatment approaches, the overall survival rate of cancer has not been improved. Colorectal cancer (CRC) is recognized as the third leading cause of neoplasm-related deaths worldwide, in large part due to its ...
Mostafa Akbarzadeh Khiavi   +2 more
doaj   +1 more source

Is porto sinusoidal vascular disease to be actively searched in patients with portal vein thrombosis? [PDF]

open access: yes, 2019
Porto sinusoidal vascular liver disease (PSVD) and portal vein thrombosis (PVT) are distinct vascular liver diseases characterized, respectively, by an intrahepatic and a prehepatic obstacle to the flow in the liver portal system. PVT may also occur as a
D'Amati, G.   +4 more
core   +1 more source

Current Advance of Therapeutic Agents in Clinical Trials Potentially Targeting Tumor Plasticity

open access: yesFrontiers in Oncology, 2019
Tumor plasticity refers to tumor cell's inherent property of transforming one type of cell to different types of cells. Tumor plasticity is the main cause of tumor relapse, metastasis and drug resistance.
Xiao-Guang Yang   +4 more
doaj   +1 more source

Hepatic metastasis with heterologous rhabdomyoblastic differentiation in a patient with gastrointestinal stromal tumor treated with imatinib

open access: yesIndian Journal of Pathology and Microbiology, 2013
Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the intestinal tract. In patients with locally advanced and/or metastatic GIST, the introduction of tyrosine kinase inhibitor, imatinib mesylate, has transformed the ...
Mukul Vij, Susama Patra, Mohamed Rela
doaj   +1 more source

Sec61 blockade therapy overrides resistance to proteasome inhibitors and immunomodulatory drugs in multiple myeloma

open access: yesFrontiers in Oncology, 2023
Multiple Myeloma (MM) is an incurable neoplasm of mature B cells and the second most prevalent hematological malignancy worldwide. While combinations of proteasome inhibitors like bortezomib (Bz) and immunomodulators (IMiDs) like lenalinomide (Len) are ...
Antoine Domenger   +6 more
doaj   +1 more source

Generation of orthotopic patient-derived xenografts from gastrointestinal stromal tumor. [PDF]

open access: yes, 2014
BackgroundGastrointestinal stromal tumor (GIST) is the most common sarcoma and its treatment with imatinib has served as the paradigm for developing targeted anti-cancer therapies.
Babicky, Michele L   +10 more
core   +3 more sources

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review) [PDF]

open access: yes, 2016
Multiple myeloma (MM) is a mature B cell neoplasm that results in multi-organ failure. The median age of onset, diverse clinical manifestations, heterogeneous survival rate, clonal evolution, intrinsic and acquired drug resistance have impact on the ...
Bebawy, M   +4 more
core   +1 more source

Research advances in platinum resistance and its treatment in ovarian cancer [PDF]

open access: yes精准医学杂志
Ovarian cancer is one of the most malignant gynecological tumors. Platinum-based chemotherapy is an important part of ovarian cancer treatment, with platinum resistance as a difficult problem in ovarian cancer treatment. Platinum resis-tance is a complex
LIU Yan, HUANG Li
doaj   +1 more source

Home - About - Disclaimer - Privacy